Table of Contents
Montelukast is a leukotriene receptor antagonist commonly used in the management of asthma and allergic rhinitis. Understanding its pharmacokinetics is essential for optimizing its therapeutic efficacy and safety.
Absorption of Montelukast
Montelukast is well absorbed after oral administration. Its bioavailability is approximately 64%, which is not significantly affected by food intake. The drug reaches peak plasma concentrations within 3 to 4 hours post-dose, indicating rapid absorption.
Distribution of Montelukast
Montelukast is extensively bound to plasma proteins, with over 99% binding primarily to albumin. This high degree of protein binding influences its distribution and interaction with other drugs. The drug is distributed broadly in body tissues, including the lungs, which are the primary site of action.
Metabolism of Montelukast
The metabolism of montelukast occurs mainly in the liver through the cytochrome P450 enzyme system, particularly CYP2C8. It undergoes minimal first-pass metabolism, and its metabolites are inactive. The metabolic process results in the formation of several metabolites, which are primarily excreted via the feces.
Excretion and Elimination
Montelukast has a half-life of approximately 3 to 6 hours in healthy adults. It is eliminated mainly through biliary excretion into the feces, with less than 5% excreted unchanged in the urine. The pharmacokinetics may be altered in patients with hepatic impairment, necessitating dose adjustments.
Clinical Implications
Understanding the pharmacokinetics of montelukast helps clinicians optimize dosing schedules, especially in patients with liver impairment or those taking other medications that affect cytochrome P450 enzymes. The rapid absorption and extensive protein binding contribute to its effectiveness in managing airway inflammation.